Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer.

Journal of controlled release : official journal of the Controlled Release Society - 10 Dec 2025

Yang Huan, Hu Lin, Su Zhiyue, Peng Fei, Wang Yuhong, Qi Chang, Shen Wenhao, Yang Kai, Zhao Jun, Guo Lingchuan, Lei Zhe

Abstract excerpt

KRAS mutations are key drivers of NSCLC, but effective targeted therapies remain scarce due to frequent resistance. EGFR phosphorylation has emerged as a central mechanism underlying acquired resistance to KRAS inhibitors. To overcome this, we developed a hybrid nanovesicle (hNV)-mediated combination therapy based on a membrane-mimetic hNV platform embedded with EGFR-targeted nanobodies (EGa1), termed EGa1-hNVs,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Nanoparticles

Share to Proto-Oncogene Proteins p21(ras)

Share to Single-Domain Antibodies

Source

Identifiers

PMID: 41130420
DOI: 10.1016/j.jconrel.2025.114345

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer.PMID 41130420Read ↗

Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer.Semantic proximity Read ↗

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co-Mutant Tumors.Semantic proximity Read ↗

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read ↗

Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer.Semantic proximity Read ↗

Effective Degradation of Wild-Type and Mutant EGFR Using Self-Assembling Peptide-Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy.Semantic proximity Read ↗

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosisSemantic proximity Read ↗

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read ↗

Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.Semantic proximity Read ↗

A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation.Semantic proximity Read ↗

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.Semantic proximity Read ↗

Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors.Semantic proximity Read ↗

Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.